Cochlioquinone A1, a new anti-angiogenic agent from Bipolaris zeicola.
Cochlioquinone A1 (CoA1) was newly isolated from the culture extract of Bipolaris zeicola as a potent anti-angiogenic agent. CoA1 inhibited in vitro angiogenesis of bovine aortic endothelial cells (BAECs) such as bFGF-induced tube formation and invasion at the concentration (1 microg/mL) without cytotoxicity. Notably, CoA1 exhibited more potent inhibition activity for the growth of BAECs than that of normal and cancer cell lines investigated in this study. These results demonstrate that CoA1 is a new anti-angiogenic agent and can be developed as a new therapeutic agent for angiogenesis-related diseases.
Jung
Hye Jin
HJ
Department of Bioscience and Biotechnology, Institute of Bioscience, Sejong University, 98 Kunja-Dong, Kwangjin-Gu, 143-747 Seoul, South Korea.
Burm Lee
Hyang
H
Lim
Chi Hwan
CH
Kim
Chang Jin
CJ
Kwon
Ho Jeong
HJ
D020533:Angiogenesis Inhibitors / Q000737:chemistry* / Q000302:isolation & purification / Q000494:pharmacology*; D000818:Animals; D001011:Aorta / Q000166:cytology; D001203:Ascomycota / Q000737:chemistry*; D016227:Benzoquinones / Q000737:chemistry* / Q000302:isolation & purification / Q000494:pharmacology*; D002417:Cattle; D002460:Cell Line; D042783:Endothelial Cells / Q000166:cytology / Q000187:drug effects; D006801:Humans; D020128:Inhibitory Concentration 50; D051379:Mice
D020533:Angiogenesis Inhibitors; D016227:Benzoquinones; C066134:cochlioquinone A